These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35090503)

  • 1. UCP1 modulates immune infiltration level and survival outcome in ovarian cancer patients.
    Huang J; Wang G; Liao K; Xie N; Deng K
    J Ovarian Res; 2022 Jan; 15(1):16. PubMed ID: 35090503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
    Peng Y; Wang H; Huang Q; Wu J; Zhang M
    J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of UCP1 and UCP2 as Potential Prognostic Markers in Breast Cancer: A Study Based on Immunohistochemical Analysis and Bioinformatics.
    Yu X; Shi M; Wu Q; Wei W; Sun S; Zhu S
    Front Cell Dev Biol; 2022; 10():891731. PubMed ID: 35874806
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.
    Lei J; He ZY; Wang J; Hu M; Zhou P; Lian CL; Hua L; Wu SG; Zhou J
    Cancer Med; 2021 Apr; 10(8):2924-2939. PubMed ID: 33742531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
    Diao B; Yang P
    Pathol Oncol Res; 2021; 27():1609855. PubMed ID: 34512203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.
    Yu L; Ding Y; Wan T; Deng T; Huang H; Liu J
    Front Immunol; 2021; 12():768115. PubMed ID: 34966389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.
    Yeung TL; Leung CS; Wong KK; Gutierrez-Hartmann A; Kwong J; Gershenson DM; Mok SC
    Oncotarget; 2017 Mar; 8(10):16951-16963. PubMed ID: 28199976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumorigenic role of Pak4 in ovarian cancer and its correlation with immune infiltration.
    Tang L; Ye H; Chen L; Dong W; Hu X; Yu L
    BMC Med Genomics; 2024 May; 17(1):148. PubMed ID: 38807162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of
    Jiang S; Yang Y; Zhang Y; Ye Q; Song J; Zheng M; Li X
    Dis Markers; 2022; 2022():9719671. PubMed ID: 35186171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
    Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
    Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment.
    Ji H; Ren M; Liu T; Sun Y
    Dis Markers; 2021; 2021():5350232. PubMed ID: 34840630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
    Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of SENP3/SMT3IP1 promotes epithelial ovarian cancer progression and forecasts poor prognosis.
    Cheng J; Su M; Jin Y; Xi Q; Deng Y; Chen J; Wang W; Chen Y; Chen L; Shi N; Mao G
    Tumour Biol; 2017 Mar; 39(3):1010428317694543. PubMed ID: 28351334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 18. KRAS modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinoma.
    Li N; Tian Y; Liu X; Pan C; Xue J
    Medicine (Baltimore); 2023 Dec; 102(52):e36597. PubMed ID: 38206735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
    Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
    Front Immunol; 2019; 10():6. PubMed ID: 30761122
    [No Abstract]   [Full Text] [Related]  

  • 20. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.